The Effects of Alpha Lipoic Acid Supplementation on The Serum Lipid Profile, Weight Loss, and Resistin Level in Women PCOS Treated with Metformin

Fatima Ali  Hussein; Sinaa Abdul Amir  Kadhim; Asma Abdul Jaleel  Swadi

doi:10.17605/cajmns.v6i4.2880

Fatima Ali Hussein University of Al-Qadisiyah, Al-Qadisiyah, Iraq
Sinaa Abdul Amir Kadhim University of Al-Qadisiyah, Al-Qadisiyah, Iraq
Asma Abdul Jaleel Swadi University of Al-Qadisiyah, Al-Qadisiyah, Iraq

DOI: https://doi.org/10.17605/cajmns.v6i4.2880

Keywords: Serum Lipids, Resistin, PCOS

Abstract

Supplements such as Alpha Lipoic Acid are becoming more and more popular as more women look for natural remedies or prescription drugs to control their symptoms. Better health outcomes and an improved quality of life can result from combining these with a customized plan. Evaluation of the combined effects of metformin, and ALA, in PCOS in terms of weight loss, serum lipid profile, and insulin resistance is the goal of the current study. The randomized, single-blind, and actively controlled clinical trial was conducted in Babylon, Iraq, between September 2024 and March 2025. The participants were divided into two groups at random. Computer-generated random numbers were used for the random assignment. Glucophage (500 mg; Merck, West Drayton, UK) was administered once daily for 2 weeks followed by 2 times a day until end of study to patients in Group Met., while patients in Group Met.+ALA got metformin as in the first group plus ALA (600 mg, Batch no. 53642; neutec, Turkey) once/ day. Every treatment was administered for a total of twelve weeks. The average body mass index, cholesterol, triglycerides, and LDL all dramatically decreased after treatment, while HDL increased (p < 0.001). The effect of Met. plus ALA was significantly more pronounced than that of the other therapeutic modality (p < 0.05). Nevertheless, resistin serum levels were not substantially impacted by any of these treatment modalities (p > 0.05). In women with PCOS, alpha lipoic acid supplements are effective and safe ways to increase the results of metformin treatment in terms of weight loss and serum lipid profile improvement.

References

N. Salari et al., “Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis,” Arch. Gynecol. Obstet., vol. 310, no. 3, pp. 1303–1314, Sep. 2024, doi: 10.1007/s00404-024-07607-x.

L. H. Zeng et al., “Polycystic Ovary Syndrome: A Disorder of Reproductive Age, Its Pathogenesis, and a Discussion on the Emerging Role of Herbal Remedies,” Front. Pharmacol., vol. 13, p. 874914, Jul. 2022, doi: 10.3389/fphar.2022.874914.

J. Dong and D. A. Rees, “Polycystic ovary syndrome: pathophysiology and therapeutic opportunities,” BMJ Med., vol. 2, no. 1, p. e000548, Oct. 2023, doi: 10.1136/bmjmed-2023-000548.

S. F. Witchel, S. E. Oberfield, and A. S. Peña, “Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls,” J. Endocr. Soc., vol. 3, no. 8, pp. 1545–1573, Jun. 2019, doi: 10.1210/js.2019-00078.

Y. Xu and J. Qiao, “Association of Insulin Resistance and Elevated Androgen Levels with Polycystic Ovarian Syndrome (PCOS): A Review of Literature,” J. Healthc. Eng., vol. 2022, pp. 1–8, Mar. 2022, doi: 10.1155/2022/9240569.

J. Tomlinson et al., “Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced?,” Diabet. Med., vol. 27, no. 5, pp. 498–515, May 2010, doi: 10.1111/j.1464-5491.2010.02994.x.

J. C. Marshall and A. Dunaif, “Should all women with PCOS be treated for insulin resistance?,” Fertil. Steril., vol. 97, no. 1, pp. 18–22, Jan. 2012, doi: 10.1016/j.fertnstert.2011.11.036.

G. M. Attia, M. M. Almouteri, and F. T. Alnakhli, “Role of Metformin in Polycystic Ovary Syndrome (PCOS)-Related Infertility,” Cureus, vol. 15, no. 8, p. e44493, Aug. 2023, doi: 10.7759/cureus.44493.

K. M. Brand, U. Gottwald-Hostalek, and A. Andag-Silva, “Update on the therapeutic role of metformin in the management of polycystic ovary syndrome: Effects on pathophysiologic process and fertility outcomes,” Womens Health, vol. 21, pp. 1–11, 2025, doi: 10.1177/17455057241311759.

A. L. G. Notaro and F. T. L. Neto, “The use of metformin in women with polycystic ovary syndrome: an updated review,” J. Assist. Reprod. Genet., vol. 39, no. 3, pp. 573–579, Mar. 2022, doi: 10.1007/s10815-022-02429-9.

A. Saxena et al., “Efficacy of optimal nutraceutical combination in treating PCOS characteristics: an in-silico assessment,” BMC Endocr. Disord., vol. 24, no. 1, p. 44, Mar. 2024, doi: 10.1186/s12902-024-01571-y.

A. Guarano et al., “Alpha Lipoic Acid Efficacy in PCOS Treatment: What Is the Truth?,” Nutrients, vol. 15, no. 14, p. 3209, Jul. 2023, doi: 10.3390/nu15143209.

A. D. Genazzani et al., “Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients,” J. Endocrinol. Invest., vol. 41, no. 5, pp. 583–590, May 2018, doi: 10.1007/s40618-017-0782-z.

A. S. Laganà et al., “Does Alpha-lipoic acid improve effects on polycystic ovary syndrome?,” Eur. Rev. Med. Pharmacol. Sci., vol. 26, no. 4, pp. 1241–1247, Feb. 2022, doi: 10.26355/eurrev_202202_28116.

M. Nasiri et al., “Modulation of hormonal, metabolic, inflammatory and oxidative stress biomarkers in women with polycystic ovary syndrome following combined (resistant and endurance) training: a randomized controlled trail,” BMC Endocr. Disord., vol. 25, no. 1, p. 1, Jan. 2025, doi: 10.1186/s12902-024-01793-0.

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS),” Hum. Reprod., vol. 19, no. 1, pp. 41–47, Jan. 2004, doi: 10.1093/humrep/deh098.

R. Jannatifar, H. Piroozmanesh, S. S. Sahraei, and E. Asa, “Combination of alpha lipoic acid and metformin supplement improve assisted reproductive technologies outcomes in polycystic ovary syndrome patients,” Anat. Cell Biol., vol. 55, no. 2, pp. 239–246, 2022, doi: 10.5115/acb.21.242.

F. Fruzzetti, A. Capozzi, A. Canu, and S. Lello, “Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome,” Gynecol. Endocrinol., vol. 35, no. 6, pp. 506–510, 2019, doi: 10.1080/09513590.2018.1540573.

S. Kucukgoncu, E. Zhou, K. B. Lucas, and C. Tek, “Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials,” Obes. Rev., vol. 18, no. 5, pp. 594–601, 2017, doi: 10.1111/obr.12528.

N. Namazi, B. Larijani, and L. Azadbakht, “Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials,” Clin. Nutr., vol. 37, no. 2, pp. 419–428, 2018, doi: 10.1016/j.clnu.2017.06.002.

E. H. Koh et al., “Effects of alpha-lipoic Acid on body weight in obese subjects,” Am. J. Med., vol. 124, no. 1, pp. 85.e1–85.e8, 2011, doi: 10.1016/j.amjmed.2010.08.005.

M. G. Carbonelli et al., “Alpha-lipoic acid supplementation: a tool for obesity therapy?,” Curr. Pharm. Des., vol. 16, no. 7, pp. 840–846, 2010, doi: 10.2174/138161210790883589.

A. E. Huerta, S. Navas-Carretero, P. L. Prieto-Hontoria, J. A. Martínez, and M. J. Moreno-Aliaga, “Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss,” Obesity, vol. 23, no. 2, pp. 313–321, 2015, doi: 10.1002/oby.20966.

Y. Wang, X. Li, Y. Guo, L. Chan, and X. Guan, “Alpha-Lipoic acid increases energy expenditure by enhancing AMPK-PGC1α signaling in skeletal muscle of aged mice,” Metabolism, vol. 59, no. 7, pp. 967–976, 2010, doi: 10.1016/j.metabol.2009.10.018.

P. L. Prieto-Hontoria, P. Pérez-Matute, M. Fernández-Galilea, J. A. Martínez, and M. J. Moreno-Aliaga, “Effects of lipoic acid on AMPK and adiponectin in adipose tissue of low- and high-fat-fed rats,” Eur. J. Nutr., vol. 52, no. 2, pp. 779–787, 2013, doi: 10.1007/s00394-012-0384-7.

H. Ansar, Z. Mazloom, F. Kazemi, and N. Hejazi, “Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients,” Saudi Med. J., vol. 32, no. 6, pp. 584–588, 2011.

A. M. McNeilly et al., “Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance,” Lipids Health Dis., vol. 10, p. 217, 2011, doi: 10.1186/1476-511X-10-217.

M. A. Abdalla et al., “Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis,” Ther. Adv. Endocrinol. Metab., vol. 13, p. 20420188221127142, 2022, doi: 10.1177/20420188221127142.

H. Shamim et al., “Role of Metformin in the Management of Polycystic Ovarian Syndrome-Associated Acne: A Systematic Review,” Cureus, vol. 14, no. 8, p. e28462, 2022, doi: 10.7759/cureus.28462.

R. Pu et al., “Effects of metformin in obesity treatment in different populations: a meta-analysis,” Ther. Adv. Endocrinol. Metab., vol. 11, p. 2042018820926000, 2020, doi: 10.1177/2042018820926000.

S. Firat, K. Elter, S. Ateş, and M. Fisunoğlu, “Does MYO and ALA Supplementation Improve PCOS Outcomes?,” Medicina, vol. 61, no. 5, p. 885, 2025.

F. J. Femi-Olabisi et al., “Alpha-lipoic acid regulates pro-inflammatory cytokines and hormones in letrozole-induced polycystic ovary syndrome in rats,” Endocr. Metab. Sci., vol. 18, p. 100245, 2025.

R. Rago et al., “Effect of myo-inositol and alpha-lipoic acid on oocyte quality in PCOS non-obese women undergoing IVF: a pilot study,” J. Biol. Regul. Homeost. Agents, vol. 29, no. 4, pp. 913–923, 2015.

A. Cianci et al., “D-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS,” Gynecol. Endocrinol., vol. 31, no. 6, pp. 483–486, 2015, doi: 10.3109/09513590.2015.1014784.

A. J. Duleba, “Medical management of metabolic dysfunction in PCOS,” Steroids, vol. 77, no. 4, pp. 306–311, 2012, doi: 10.1016/j.steroids.2011.11.014.

E. Diamanti-Kandarakis et al., “Metformin administration improves endothelial function in women with PCOS,” Eur. J. Endocrinol., vol. 152, no. 5, pp. 749–756, 2005, doi: 10.1530/eje.1.01910.

B. Banaszewska, L. Pawelczyk, R. Z. Spaczynski, and A. J. Duleba, “Effects of simvastatin and metformin on PCOS after six months of treatment,” J. Clin. Endocrinol. Metab., vol. 96, no. 11, pp. 3493–3501, 2011, doi: 10.1210/jc.2011-0501.

S. H. Lin et al., “Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed T2DM: a cohort study,” PeerJ, vol. 6, p. e4578, 2018, doi: 10.7717/peerj.4578.

G. Basios et al., “The impact of metformin on adiponectin and resistin levels in women with PCOS: a prospective clinical study,” Gynecol. Endocrinol., vol. 31, no. 2, pp. 136–140, 2015, doi: 10.3109/09513590.2014.975684.

H. D. Najim, I. A. Majeed, and A. M. Rahmah, “Effects of Metformin &/or Glimepiride on Resistin Level and Related Biochemical Markers in Type 2 Diabetes Mellitus,” Al Mustansiriyah J. Pharm. Sci., vol. 14, no. 2, pp. 78–88, 2014.